发布求助
文献互助 智能选刊 最新文献

Gastroenterology and Hepatology最新文献

筛选
英文 中文
From Past to Present: The Evolution of Pharmacologic Therapies for Eosinophilic Esophagitis. 从过去到现在：嗜酸性粒细胞性食管炎药物治疗的演变。
Gastroenterology and Hepatology Pub Date : 2025-05-01
Susie Min, Joy W Chang
{"title":"From Past to Present: The Evolution of Pharmacologic Therapies for Eosinophilic Esophagitis.","authors":"Susie Min, Joy W Chang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Within the evolving landscape of eosinophilic esophagitis (EoE) management are multiple pharmacologic treatment modalities, including proton pump inhibitors (PPIs), swallowed topical corticosteroids, and novel biologic agents. Studies to date on PPIs and corticosteroids have provided valuable insights into how to define the disease, and recently approved biologic therapies are heralding a new era of EoE management. Although progress has been made in treating this complex inflammatory, fibrostenotic disease and in understanding its pathophysiology, several knowledge gaps persist and continue to be investigated. In addition, unknowns exist regarding the long-term safety and efficacy of new EoE treatments and how to position therapies in diverse patient populations. This article aims to provide historical context for the current landscape of pharmacologic treatments in EoE and perspectives on how future development may improve understanding and management of this complex disease.</p>","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 5","pages":"298-303"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on the Management of Cholestatic Pruritus. 胆汁淤积性瘙痒症的治疗进展。
Gastroenterology and Hepatology Pub Date : 2025-05-01
Kimberly Brown
{"title":"Update on the Management of Cholestatic Pruritus.","authors":"Kimberly Brown","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 5","pages":"315-317"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlights From the Recent APASL Guidelines on Systemic Therapy for Hepatocellular Carcinoma. 最近APASL关于肝细胞癌全身治疗指南的亮点。
Gastroenterology and Hepatology Pub Date : 2025-05-01
George Lau
{"title":"Highlights From the Recent APASL Guidelines on Systemic Therapy for Hepatocellular Carcinoma.","authors":"George Lau","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 5","pages":"272-274"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Promise of Digital Therapeutics for Disorders of Gut-Brain Interaction. 肠脑相互作用紊乱的数字治疗前景。
Gastroenterology and Hepatology Pub Date : 2025-05-01
Kyle Staller
{"title":"The Promise of Digital Therapeutics for Disorders of Gut-Brain Interaction.","authors":"Kyle Staller","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 5","pages":"328-331"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the Use of Digital Therapeutics for Patients With Disorders of Gut-Brain Interaction. 探索数字治疗在肠-脑相互作用疾病患者中的应用。
Gastroenterology and Hepatology Pub Date : 2025-05-01
Gary R Lichtenstein
{"title":"Exploring the Use of Digital Therapeutics for Patients With Disorders of Gut-Brain Interaction.","authors":"Gary R Lichtenstein","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 5","pages":"271"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Missing the Mark: Optimizing Endoscopy for Intestinal Metaplasia and Gastric Cancer Detection in the United States. 缺失的标志：优化内镜肠化生和胃癌检测在美国。
Gastroenterology and Hepatology Pub Date : 2025-05-01
Joo Ha Hwang
{"title":"Missing the Mark: Optimizing Endoscopy for Intestinal Metaplasia and Gastric Cancer Detection in the United States.","authors":"Joo Ha Hwang","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 5","pages":"321-324"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights Into Cell Therapies for Patients With Inflammatory Bowel Disease. 炎性肠病患者细胞疗法的新见解
Gastroenterology and Hepatology Pub Date : 2025-05-01
Louis J Cohen
{"title":"Insights Into Cell Therapies for Patients With Inflammatory Bowel Disease.","authors":"Louis J Cohen","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 5","pages":"311-314"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Looking Toward the Future: Emerging Therapies for Hepatocellular Carcinoma. 展望未来：肝细胞癌的新疗法。
Gastroenterology and Hepatology Pub Date : 2025-05-01
Sanjana Rao, Sean-Patrick Prince, Sirisha Gaddipati, Lynn Feun, Nkiruka Ezenwajiaku, Paul Martin, Patricia D Jones
{"title":"Looking Toward the Future: Emerging Therapies for Hepatocellular Carcinoma.","authors":"Sanjana Rao, Sean-Patrick Prince, Sirisha Gaddipati, Lynn Feun, Nkiruka Ezenwajiaku, Paul Martin, Patricia D Jones","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related deaths worldwide. Despite the decreasing prevalence of hepatitis C, the burden of HCC is expected to rise owing to the increasing prevalence of metabolic syndrome and increased global alcohol consumption. Guideline-concordant screening with ultrasound every 6 months has been associated with increased rates of early-stage detection and receipt of curative treatment. However, most patients with cirrhosis do not undergo screening, with HCC often diagnosed only at an advanced stage when curative resection or ablation is not feasible. Systemic medical therapy is indicated in patients diagnosed with infiltrative or advanced HCC, or when early-stage disease progresses or recurs after resection, transplant, or other locoregional therapy. Sorafenib was approved as first-line therapy for HCC in 2007. Since 2017, there has been an exponential rate of approval of novel agents targeting HCC, including lenvatinib, regorafenib, and cabozantinib. Checkpoint inhibitors, including pembrolizumab, nivolumab, ipilimumab, and combination therapy with atezolizumab plus bevacizumab and durvalumab plus tremelimumab, have expanded treatment options. This article describes treatment for all HCC stages, with a brief discussion of locoregional therapy for context, as some emerging treatment regimens combine locoregional and systemic therapies. The article highlights approved systemic therapies that are guideline-endorsed and emerging therapies for advanced HCC.</p>","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 5","pages":"286-297"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing the Diagnostic Yield of EGD for Diagnosis of Barrett Esophagus Through Methylated DNA Biomarker Triage. 甲基化DNA生物标志物分类提高EGD诊断Barrett食管的诊断率。
Gastroenterology and Hepatology Pub Date : 2025-04-01
Jayde E Kurland, Sheena B Patel, Richard Englehardt, Seper Dezfoli, Daniel M Tseng, Michael W Foutz, Paul S Bradley, Badi Eghterafi, Victoria T Lee, Suman Verma, Brian J deGuzman, Lishan Aklog
{"title":"Enhancing the Diagnostic Yield of EGD for Diagnosis of Barrett Esophagus Through Methylated DNA Biomarker Triage.","authors":"Jayde E Kurland, Sheena B Patel, Richard Englehardt, Seper Dezfoli, Daniel M Tseng, Michael W Foutz, Paul S Bradley, Badi Eghterafi, Victoria T Lee, Suman Verma, Brian J deGuzman, Lishan Aklog","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>EsoGuard (EG) is a methylated DNA assay for cells collected nonendoscopically with EsoCheck for detection of Barrett esophagus (BE) and can be utilized as a triage to esophagogastroduodenoscopy (EGD) in patients meeting clinical criteria for BE screening. EG triage may enrich the population undergoing EGD, increasing BE diagnosis without overburdening endoscopy resources.</p><p><strong>Aim: </strong>To test the hypothesis that EGDs performed on patients who test positive on EG have higher diagnostic yields than screening EGDs alone.</p><p><strong>Methods: </strong>We collected real-world retrospective data from EG-positive patients for whom EGD diagnoses were available. The diagnostic yield of these EGDs was measured by the BE detection rate. The yield of screening EGDs was estimated by literature-established disease prevalence (10.6%). The hypothesis was tested using t-test for single proportions at a one-sided 5% significance level.</p><p><strong>Results: </strong>Among 209 patients, 60 (28.7%) had specialized intestinal metaplasia but 10 (4.8%) had less than 1 cm of nondysplastic disease. Because the American College of Gastroenterology (ACG) definition of BE requires disease length of at least 1 cm, these patients were excluded from analysis. In the analyzed population, we observed a 2.4-fold increase in BE detection compared with the 10.6% performance goal. There was a 2.7-fold increase in the cohort meeting ACG screening criteria and a 2.5-fold increase among those meeting ACG criteria who were aged 65 years and older.</p><p><strong>Conclusion: </strong>EG triage enriches the population undergoing EGD for BE detection. Compared with screening EGD alone, it improves diagnostic yield. This may help direct more efficient use of endoscopy resources to improve disease detection in at-risk patients.</p>","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 4","pages":"210-217"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What Is Moderate to Severe Inflammatory Bowel Disease? 什么是中度至重度炎症性肠病？
Gastroenterology and Hepatology Pub Date : 2025-04-01
Laurent Peyrin-Biroulet
{"title":"What Is Moderate to Severe Inflammatory Bowel Disease?","authors":"Laurent Peyrin-Biroulet","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 4","pages":"247-249"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信